Is SRRK or BNTX more profitable?

Scholar Rock has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% BioNTech -63.54% -6.86% -6.00%

Does the media refer more to SRRK or BNTX?

In the previous week, BioNTech had 10 more articles in the media than Scholar Rock. MarketBeat recorded 21 mentions for BioNTech and 11 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.61 beat BioNTech's score of 0.44 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, INCY or SRRK?

Incyte has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.82B 4.23 $1.29B $7.85 15.47 Scholar Rock N/A N/A -$377.94M -$3.45 N/A

Is INCY or SRRK more profitable?

Incyte has a net margin of 27.71% compared to Scholar Rock's net margin of 0.00%. Incyte's return on equity of 29.93% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% Scholar Rock N/A -160.19% -87.18%

Does the media prefer INCY or SRRK?

In the previous week, Incyte had 8 more articles in the media than Scholar Rock. MarketBeat recorded 19 mentions for Incyte and 11 mentions for Scholar Rock. Incyte's average media sentiment score of 0.98 beat Scholar Rock's score of 0.61 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 9 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ROIV or SRRK?

In the previous week, Roivant Sciences had 30 more articles in the media than Scholar Rock. MarketBeat recorded 41 mentions for Roivant Sciences and 11 mentions for Scholar Rock. Roivant Sciences' average media sentiment score of 0.62 beat Scholar Rock's score of 0.61 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 13 Very Positive mention(s) 8 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SRRK or GMAB more profitable?

Genmab A/S has a net margin of 19.08% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Genmab A/S 19.08% 14.89% 7.73%

Does the media refer more to SRRK or GMAB?

In the previous week, Scholar Rock had 5 more articles in the media than Genmab A/S. MarketBeat recorded 11 mentions for Scholar Rock and 6 mentions for Genmab A/S. Scholar Rock's average media sentiment score of 0.61 beat Genmab A/S's score of 0.40 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SRRK or UTHR?

In the previous week, United Therapeutics had 12 more articles in the media than Scholar Rock. MarketBeat recorded 23 mentions for United Therapeutics and 11 mentions for Scholar Rock. United Therapeutics' average media sentiment score of 0.88 beat Scholar Rock's score of 0.61 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 13 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Scholar Rock (SRRK) Competitors

$55.41 -0.26 (-0.47%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$61.95 +6.54 (+11.80%)

As of 09/11/2026 07:59 PM Eastern

Compare

SRRK vs. BNTX, INCY, ROIV, GMAB, and UTHR

Should you buy Scholar Rock stock or one of its competitors? Scholar Rock's main competitors and comparable companies include BioNTech (BNTX), Incyte (INCY), Roivant Sciences (ROIV), Genmab A/S (GMAB), and United Therapeutics (UTHR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Scholar Rock compare to BioNTech?

Scholar Rock (NASDAQ:SRRK) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Scholar Rock has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

In the previous week, BioNTech had 10 more articles in the media than Scholar Rock. MarketBeat recorded 21 mentions for BioNTech and 11 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.61 beat BioNTech's score of 0.44 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Scholar Rock currently has a consensus price target of $58.77, suggesting a potential upside of 6.06%. BioNTech has a consensus price target of $126.00, suggesting a potential upside of 30.26%. Given BioNTech's higher probable upside, analysts clearly believe BioNTech is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.06
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68

Scholar Rock has higher earnings, but lower revenue than BioNTech. Scholar Rock is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
BioNTech	$2.65B	9.23	-$1.29B	-$7.83	N/A

Scholar Rock has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
BioNTech	-63.54%	-6.86%	-6.00%

Summary

BioNTech beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Incyte?

Incyte (NASDAQ:INCY) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

In the previous week, Incyte had 8 more articles in the media than Scholar Rock. MarketBeat recorded 19 mentions for Incyte and 11 mentions for Scholar Rock. Incyte's average media sentiment score of 0.98 beat Scholar Rock's score of 0.61 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	9 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Incyte shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 16.2% of Incyte shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Incyte has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.82B	4.23	$1.29B	$7.85	15.47
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Incyte presently has a consensus price target of $124.05, suggesting a potential upside of 2.12%. Scholar Rock has a consensus price target of $58.77, suggesting a potential upside of 6.06%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52
Scholar Rock	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.06

Incyte has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Incyte has a net margin of 27.71% compared to Scholar Rock's net margin of 0.00%. Incyte's return on equity of 29.93% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Scholar Rock	N/A	-160.19%	-87.18%

Summary

Incyte beats Scholar Rock on 13 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Roivant Sciences has higher revenue and earnings than Scholar Rock. Roivant Sciences is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$7.53M	3,914.66	-$299.77M	-$0.53	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Roivant Sciences has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Roivant Sciences presently has a consensus price target of $40.63, indicating a potential downside of 0.48%. Scholar Rock has a consensus price target of $58.77, indicating a potential upside of 6.06%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Scholar Rock	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.06

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Roivant Sciences had 30 more articles in the media than Scholar Rock. MarketBeat recorded 41 mentions for Roivant Sciences and 11 mentions for Scholar Rock. Roivant Sciences' average media sentiment score of 0.62 beat Scholar Rock's score of 0.61 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	13 Very Positive mention(s)	8 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Scholar Rock	N/A	-160.19%	-87.18%

Summary

Roivant Sciences beats Scholar Rock on 8 of the 15 factors compared between the two stocks.

How does Scholar Rock compare to Genmab A/S?

Scholar Rock (NASDAQ:SRRK) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Genmab A/S has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Genmab A/S	$4.13B	4.90	$963M	$1.27	25.57

In the previous week, Scholar Rock had 5 more articles in the media than Genmab A/S. MarketBeat recorded 11 mentions for Scholar Rock and 6 mentions for Genmab A/S. Scholar Rock's average media sentiment score of 0.61 beat Genmab A/S's score of 0.40 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S has a net margin of 19.08% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Genmab A/S	19.08%	14.89%	7.73%

Scholar Rock currently has a consensus price target of $58.77, suggesting a potential upside of 6.06%. Genmab A/S has a consensus price target of $39.50, suggesting a potential upside of 21.65%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.06
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Scholar Rock has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Summary

Genmab A/S beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to United Therapeutics?

Scholar Rock (NASDAQ:SRRK) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

United Therapeutics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
United Therapeutics	$3.18B	6.70	$1.33B	$27.95	17.79

Scholar Rock has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

In the previous week, United Therapeutics had 12 more articles in the media than Scholar Rock. MarketBeat recorded 23 mentions for United Therapeutics and 11 mentions for Scholar Rock. United Therapeutics' average media sentiment score of 0.88 beat Scholar Rock's score of 0.61 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	13 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock presently has a consensus target price of $58.77, suggesting a potential upside of 6.06%. United Therapeutics has a consensus target price of $646.00, suggesting a potential upside of 29.95%. Given United Therapeutics' higher possible upside, analysts plainly believe United Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.06
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has a net margin of 41.56% compared to Scholar Rock's net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
United Therapeutics	41.56%	20.18%	17.98%

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

United Therapeutics beats Scholar Rock on 12 of the 16 factors compared between the two stocks.

Get Scholar Rock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRRK vs. The Competition

Export

Metric	Scholar Rock	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.78B	$3.84B	$7.15B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-16.06	14.25	275.24	25.29
Price / Sales	N/A	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	22.99	15.12	10.33	6.20
Net Income	-$377.94M	-$22.86M	$3.50B	$358.50M
7 Day Performance	0.14%	-4.34%	-3.32%	-2.35%
1 Month Performance	2.95%	-0.02%	-0.41%	-2.77%
1 Year Performance	74.96%	40.64%	19.21%	7.63%

Scholar Rock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRRK Scholar Rock	1.8004 of 5 stars	$55.41 -0.5%	$58.77 +6.1%	+74.0%	$6.78B	N/A	N/A	289	News Coverage Analyst Forecast
BNTX BioNTech	4.2591 of 5 stars	$103.76 flat	$127.44 +22.8%	-7.3%	$26.24B	$3.25B	N/A	7,807	Analyst Downgrade Insider Trade
INCY Incyte	3.4992 of 5 stars	$126.75 flat	$124.05 -2.1%	+41.0%	$25.69B	$5.14B	16.15	2,844	News Coverage Positive News Analyst Forecast
ROIV Roivant Sciences	1.5148 of 5 stars	$34.93 flat	$35.14 +0.6%	+183.3%	$25.23B	$8.26M	N/A	860	News Coverage Analyst Forecast Options Volume
GMAB Genmab A/S	4.3603 of 5 stars	$33.60 flat	$39.50 +17.6%	+13.5%	$20.96B	$3.72B	26.46	3,029

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRRK) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scholar Rock (SRRK) Competitors

SRRK vs. BNTX, INCY, ROIV, GMAB, and UTHR

How does Scholar Rock compare to BioNTech?

Summary

How does Scholar Rock compare to Incyte?

Summary

How does Scholar Rock compare to Roivant Sciences?

Summary

How does Scholar Rock compare to Genmab A/S?

Summary

How does Scholar Rock compare to United Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scholar Rock (SRRK) Competitors

SRRK vs. BNTX, INCY, ROIV, GMAB, and UTHR

How does Scholar Rock compare to BioNTech?

Which has more volatility & risk, SRRK or BNTX?

Does the media refer more to SRRK or BNTX?

Do insiders & institutionals hold more shares of SRRK or BNTX?

Do analysts recommend SRRK or BNTX?

Which has higher valuation & earnings, SRRK or BNTX?

Is SRRK or BNTX more profitable?

Summary

How does Scholar Rock compare to Incyte?

Does the media prefer INCY or SRRK?

Do institutionals and insiders hold more shares of INCY or SRRK?

Which has better earnings & valuation, INCY or SRRK?

Do analysts prefer INCY or SRRK?

Which has more volatility & risk, INCY or SRRK?

Is INCY or SRRK more profitable?

Summary

How does Scholar Rock compare to Roivant Sciences?

Which has better earnings & valuation, ROIV or SRRK?

Which has more volatility & risk, ROIV or SRRK?

Do analysts rate ROIV or SRRK?

Do insiders and institutionals believe in ROIV or SRRK?

Does the media prefer ROIV or SRRK?

Is ROIV or SRRK more profitable?

Summary

How does Scholar Rock compare to Genmab A/S?

Which has better earnings & valuation, SRRK or GMAB?

Does the media refer more to SRRK or GMAB?

Is SRRK or GMAB more profitable?

Do analysts rate SRRK or GMAB?

Do insiders & institutionals believe in SRRK or GMAB?

Which has more volatility and risk, SRRK or GMAB?

Summary

How does Scholar Rock compare to United Therapeutics?

Which has higher earnings & valuation, SRRK or UTHR?

Which has more volatility & risk, SRRK or UTHR?

Does the media refer more to SRRK or UTHR?

Do analysts rate SRRK or UTHR?

Is SRRK or UTHR more profitable?

Do insiders and institutionals have more ownership in SRRK or UTHR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools